Biotechnology There was bad news for Centocor Ortho Biotech, a Johnson & Johnson (NYSE: JNJ) company, yesterday, after it received a decision from the US Court of Appeals for the Federal Circuit in Washington DC overturning a 2009 federal court jury verdict that awarded the company $1.67 billion after finding Abbott Laboratories (NYSE: ABT) liable for patent infringement involving Abbott's biggest selling product, Humira (adalimumab), which generated sales of $6.55 billion last year, including $2.87 billion in the USA. 24 February 2011